Show simple item record

dc.contributor.authorBorges do Nascimento, Israel Júnior
dc.contributor.authorCacic, Nensi
dc.contributor.authorAbdulazeem, Hebatullah Mohamed
dc.contributor.authorvon Groote, Thilo Caspar
dc.contributor.authorJayarajah, Umesh
dc.contributor.authorWeerasekara, Ishanka
dc.contributor.authorEsfahani, Meisam Abdar
dc.contributor.authorCivile, Vinicius Tassoni
dc.contributor.authorMarusic, Ana
dc.contributor.authorJeroncic, Ana
dc.contributor.authorCarvas Junior, Nelson
dc.contributor.authorPericic, Tina Poklepovic
dc.contributor.authorZakarija-Grkovic, Irena
dc.contributor.authorMeirelles Guimarães, Silvana Mangeon
dc.contributor.authorLuigi Bragazzi, Nicola
dc.contributor.authorBjorklund, Maria
dc.contributor.authorSofi-Mahmudi, Ahmad
dc.contributor.authorAltujjar, Mohammad
dc.contributor.authorTian, Maoyi
dc.contributor.authorArcani, Diana Maria Cespedes
dc.contributor.authorO'Mathúna, Dónal P
dc.contributor.authorMarcolino, Milena Soriano
dc.date.accessioned2020-12-23T13:12:22Z
dc.date.available2020-12-23T13:12:22Z
dc.date.issued2020-03-30
dc.identifier.issn2077-0383
dc.identifier.pmid32235486
dc.identifier.doi10.3390/jcm9040941
dc.identifier.urihttp://hdl.handle.net/10147/628656
dc.descriptionA growing body of literature on the 2019 novel coronavirus (SARS-CoV-2) is becoming available, but a synthesis of available data has not been conducted. We performed a scoping review of currently available clinical, epidemiological, laboratory, and chest imaging data related to the SARS-CoV-2 infection. We searched MEDLINE, Cochrane CENTRAL, EMBASE, Scopus and LILACS from 01 January 2019 to 24 February 2020. Study selection, data extraction and risk of bias assessment were performed by two independent reviewers. Qualitative synthesis and meta-analysis were conducted using the clinical and laboratory data, and random-effects models were applied to estimate pooled results. A total of 61 studies were included (59,254 patients). The most common disease-related symptoms were fever (82%, 95% confidence interval (CI) 56%-99%; n = 4410), cough (61%, 95% CI 39%-81%; n = 3985), muscle aches and/or fatigue (36%, 95% CI 18%-55%; n = 3778), dyspnea (26%, 95% CI 12%-41%; n = 3700), headache in 12% (95% CI 4%-23%, n = 3598 patients), sore throat in 10% (95% CI 5%-17%, n = 1387) and gastrointestinal symptoms in 9% (95% CI 3%-17%, n = 1744). Laboratory findings were described in a lower number of patients and revealed lymphopenia (0.93 × 109/L, 95% CI 0.83-1.03 × 109/L, n = 464) and abnormal C-reactive protein (33.72 mg/dL, 95% CI 21.54-45.91 mg/dL; n = 1637). Radiological findings varied, but mostly described ground-glass opacities and consolidation. Data on treatment options were limited. All-cause mortality was 0.3% (95% CI 0.0%-1.0%; n = 53,631). Epidemiological studies showed that mortality was higher in males and elderly patients. The majority of reported clinical symptoms and laboratory findings related to SARS-CoV-2 infection are non-specific. Clinical suspicion, accompanied by a relevant epidemiological history, should be followed by early imaging and virological assay.en_US
dc.description.abstractA growing body of literature on the 2019 novel coronavirus (SARS-CoV-2) is becoming available, but a synthesis of available data has not been conducted. We performed a scoping review of currently available clinical, epidemiological, laboratory, and chest imaging data related to the SARS-CoV-2 infection. We searched MEDLINE, Cochrane CENTRAL, EMBASE, Scopus and LILACS from 01 January 2019 to 24 February 2020. Study selection, data extraction and risk of bias assessment were performed by two independent reviewers. Qualitative synthesis and meta-analysis were conducted using the clinical and laboratory data, and random-effects models were applied to estimate pooled results. A total of 61 studies were included (59,254 patients). The most common disease-related symptoms were fever (82%, 95% confidence interval (CI) 56%-99%; n = 4410), cough (61%, 95% CI 39%-81%; n = 3985), muscle aches and/or fatigue (36%, 95% CI 18%-55%; n = 3778), dyspnea (26%, 95% CI 12%-41%; n = 3700), headache in 12% (95% CI 4%-23%, n = 3598 patients), sore throat in 10% (95% CI 5%-17%, n = 1387) and gastrointestinal symptoms in 9% (95% CI 3%-17%, n = 1744). Laboratory findings were described in a lower number of patients and revealed lymphopenia (0.93 × 109/L, 95% CI 0.83-1.03 × 109/L, n = 464) and abnormal C-reactive protein (33.72 mg/dL, 95% CI 21.54-45.91 mg/dL; n = 1637). Radiological findings varied, but mostly described ground-glass opacities and consolidation. Data on treatment options were limited. All-cause mortality was 0.3% (95% CI 0.0%-1.0%; n = 53,631). Epidemiological studies showed that mortality was higher in males and elderly patients. The majority of reported clinical symptoms and laboratory findings related to SARS-CoV-2 infection are non-specific. Clinical suspicion, accompanied by a relevant epidemiological history, should be followed by early imaging and virological assay.
dc.language.isoenen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectmeta-analysisen_US
dc.subjectnovel coronavirusen_US
dc.subjectScoping reviewen_US
dc.titleNovel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dc.identifier.journalJournal of clinical medicineen_US
dc.source.journaltitleJournal of clinical medicine
dc.source.volume9
dc.source.issue4
refterms.dateFOA2020-12-23T13:12:23Z
dc.source.countrySwitzerland


Files in this item

Thumbnail
Name:
jcm-09-00941.pdf
Size:
714.9Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record